Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era-Reference-Cited by-同舟云学术

Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era

Published:2024-08-30 Issue: Volume: Page:
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Donzelli Livia,Antonacci M.,Zhdanovskaya N.,Petrucci L.,Di Palma M.,Martelli M.,Di Rocco A.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05962-y.pdf

Reference18 articles.

1. Derenzini E, Zinzani PL, Cheson BD (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma 55(7):1471–1478. https://doi.org/10.3109/10428194.2013.842986

2. Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus Rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389. https://doi.org/10.1200/JCO.2005.08.100

3. Rummel M, Kaiser U, Balser C, Study Group Indolent Lymphomas (2016) Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 17(1):57–66. https://doi.org/10.1016/S1470-2045(15)00447-7. Erratum in: Lancet Oncol. 2016;17(1):e6

4. Ohmachi K, Ando K, Ogura M et al (2010) Japanese Bendamustine Lymphoma Study Group. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064. https://doi.org/10.1111/j.1349-7006.2010.01635.x

5. Rummel MJ, Niederle N, Maschmeyer G, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2. Erratum in: Lancet. 2013 Apr